In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration-Reference-Cited by-同舟云学术

In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration

Published:2000-08 Issue:8 Volume:44 Page:2205-2206
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jiang Zhi-Dong¹,Ke Shi²,Palazzini Ernesto³,Riopel Lise⁴,Dupont Herbert¹⁵

Affiliation:

1. Center for Infectious Disease, School of Public Health and Medical School, University of Texas—Houston,1

2. University of Texas M.D. Anderson Cancer Center,2 and

3. Alfa Wassermann, S.p.A. Bologna, Italy3; and

4. Salix Pharmaceuticals Inc., Palo Alto, California4

5. St. Luke's Episcopal Hospital and Baylor College of Medicine,5 Houston, Texas;

Abstract

ABSTRACT Rifaximin showed moderately high MICs (the MIC at which 90% of the isolates tested were inhibited = 50 μg/ml) for 145 bacterial enteropathogens from patients with traveler's diarrhea acquired in Mexico during the summers of 1997 and 1998. Rifaximin concentrations in stool the day after oral administration (800 mg daily for 3 days) were high (average, 7,961 μg/g), proving the value of the drug.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.44.8.2205-2206.2000

Reference13 articles.

1. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin.;Corazza G. R.;J. Int. Med. Res.,1988

2. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.;Descombe J. J.;Int. J. Clin. Pharmacol. Res.,1994

3. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone.;DuPont H. L.;N. Engl. J. Med.,1982

4. Prevention and treatment of traveler's diarrhea.;DuPont H. L.;N. Engl. J. Med.,1993

5. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.;DuPont H. L.;Digestion,1998

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of rifaximin in liver diseases;Biomedicine & Pharmacotherapy;2024-09

2. Repurposing Rifaximin against Klebsiella pneumoniae via Targeting of Transcription Anti-termination Protein RfaH for Novel Antimicrobial Development;2024-08-07

3. Effect of Trimebutine and Rifaximin on Breath Hydrogen and Methane by Glucose Breath Test in Patients With Functional Bloating: A Randomized Double-blind Clinical Trial;Journal of Neurogastroenterology and Motility;2024-04-30

4. The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review;Clinical Microbiology Reviews;2023-12-20

5. Diverticular Disease and Rifaximin: An Evidence-Based Review;Antibiotics;2023-02-23